Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study

Appropriate protocol for the sequential treatment of metastatic renal cell carcinoma (mRCC) has not been established yet. Some mRCC cases with favorable risk were reported to achieve complete remission and durable response using interferon alfa (IFNα) + low dose interleukin-2 (IL-2). Cytokine therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadono, Yoshifumi, Konaka, Hiroyuki, Izumi, Kouji, Anai, Satoshi, Fujimoto, Kiyohide, Ishibashi, Kei, Kawai, Noriyasu, Kato, Taku, Iba, Akinori, Masumori, Naoya, Yoshimura, Kenichi, Mizokami, Atsushiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610625/
https://www.ncbi.nlm.nih.gov/pubmed/31312749
http://dx.doi.org/10.1016/j.conctc.2019.100403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610625/
https://www.ncbi.nlm.nih.gov/pubmed/31312749
http://dx.doi.org/10.1016/j.conctc.2019.100403

Ejemplares similares